Maria, 68, left the hospital last winter after a heart failure flare-up. She followed her diet, took her pills, and felt okay. But three months later, she was back — weak, short of breath, and scared.
She’s not alone. Over 6 million Americans live with heart failure. Many are like Maria — doing their best but still ending up back in the hospital.
Doctors have tools to track heart health. But they often miss who’s truly at risk until it’s too late.
Now, a new clue from a simple blood test may change that.
This blood marker could save lives
Heart doctors have long watched ejection fraction — how well the heart pumps. But two types — reduced (HFrEF) and mildly reduced (HFmrEF) — still leave many patients slipping through the cracks.
Treatments help. But knowing who needs more help, when, has been a guessing game.
Until now.
A new study finds a hidden signal in routine blood work: the lactate dehydrogenase-to-albumin ratio, or LAR.
Think of your body like a city. Lactate dehydrogenase (LDH) is like a smoke alarm — it goes off when cells are damaged or stressed. Albumin is like a delivery truck — it carries nutrients and keeps fluid balanced in the bloodstream.
When LDH is high and albumin is low, it’s like seeing smoke and broken trucks. The city is under stress — and not getting the supplies it needs.
That’s what a high LAR shows.
And in heart failure, that combo spells trouble.
The study looked at 1,084 patients hospitalized with HFrEF or HFmrEF. Researchers checked their LAR at admission and followed them for nearly two and a half years.
They found:
- Patients with high LAR were 60% more likely to be readmitted for heart failure
- They were twice as likely to die from any cause
- And their risk of dying or being rehospitalized jumped by 65%
These numbers held even after adjusting for age, kidney function, and other common risks.
That’s what makes this finding stand out.
LAR wasn’t just linked to risk — it added new information doctors didn’t already have.
Using standard tools, doctors can predict risk about 65% of the time. Adding LAR bumped that up — making predictions more accurate.
But there’s a catch.
LAR isn’t used in hospitals today. It’s not on the standard lab report. And no one knows yet if lowering LAR — say, by treating inflammation or improving nutrition — actually prevents bad outcomes.
Still, experts say this could be a game-changer for spotting high-risk patients early.
“The beauty of LAR is that both LDH and albumin are already measured in most hospitals,” said one researcher involved in the study. “No new tests needed — just a new way of looking at old data.”
For patients, this means doctors may soon have a better way to decide who needs closer follow-up, home visits, or stronger treatments.
But this doesn’t mean you should ask for an LAR test tomorrow.
It’s not ready for prime time.
The study looked back at past records — it didn’t test whether using LAR to guide care actually helps people live longer or stay out of the hospital.
Also, all patients were from one hospital system. Results might differ in younger, healthier, or more diverse groups.
And while the link is strong, it’s not proof that high LAR causes worse outcomes — only that they happen together.
Still, the signal is clear enough to act on — in research.
Next, scientists need to test LAR in real-time care. Can doctors use it to make better choices? Does it help patients avoid readmissions?
Clinical trials are likely needed to answer those questions. That could take years.
But for millions living with heart failure, even a small edge in prediction could mean more time at home — and fewer trips back to the hospital.
The road ahead is cautious but hopeful.
One day, a simple number — made from two common blood tests — might help doctors protect hearts before they fail again.
